Stem-loop aptamers inhibiting complement factor D
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are inadequate for age-related macular degeneration (AMD), particularly dry AMD and geographic atrophy, and childhood-onset Stargardt Disease, as there are no FDA-approved treatments for these conditions, leading to significant visual impairment and blindness.
Innovation Solution
Development of aptamers with specific nucleic acid sequences that selectively bind to complement factor D (fD), inhibiting its function, which is implicated in the progression of these diseases, thereby modulating the alternative complement pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no treatment is provided for dry AMD and geographic atrophy, then the disease progresses leading to vision loss, but current treatments are inadequate or non-existent
Solution Approach 1:
The patent introduces aptamers as intermediary molecules that specifically bind to complement factor D, blocking its interaction with C3bB complex and preventing alternative complement pathway activation. This intermediary approach provides a targeted therapeutic mechanism where the aptamer mediates between the pathological complement activation and the desired inhibition, offering a novel treatment avenue for dry AMD and geographic atrophy where no approved therapies exist.
2Reliability
If the alternative complement pathway is activated, then immune response is enhanced, but it causes damage to retinal cells leading to disease progression
Solution Approach 1:
The patent converts the harmful effect of alternative complement pathway activation into a beneficial therapeutic outcome by using aptamers to specifically inhibit factor D. The same complement system that causes retinal cell damage through uncontrolled activation is now therapeutically modulated, transforming the pathological process into a controlled therapeutic mechanism that protects retinal cells while maintaining necessary immune functions.
3Object-affected harmful factors
If complement factor D activity is inhibited, then retinal cell damage is reduced, but the mechanism must be highly specific to avoid affecting other complement pathways
Solution Approach 1:
The patent applies local quality by designing aptamers with specific structural features (stem-loop configurations with particular loop sizes and base compositions) that confer high specificity for factor D. The aptamers are engineered with localized binding regions that recognize specific epitopes on factor D, ensuring that inhibition is targeted precisely at the factor D-C3bB interaction without affecting other complement pathways or molecules, thus achieving both therapeutic efficacy and molecular precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers effectively inhibit complement factor D activity, potentially slowing or reversing the progression of AMD and Stargardt Disease by blocking the alternative complement pathway, offering a therapeutic approach for these currently untreatable conditions.
Implementation Method 1
an aptamer is provided comprising a nucleic acid sequence that selectively binds to complement factor D (fD)
Data Source
AI summary
The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease. In some cases, stem-loop aptamers are provided for the inhibition of Factor D.